{"filing":{"accession_number":"0001628280-26-044627","cik":"0001655759","ticker":"ARVN","company_name":"ARVINAS, INC.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"arvn-20260622.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026044627/arvn-20260622.htm"},"events":[{"id":12756,"run_id":11315,"accession_number":"0001628280-26-044627","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Dr. Noah Berkowitz, the Company's chief medical officer, is departing effective July 3, 2026. While the disclosure includes severance terms (base salary continuation, health coverage, and RSU acceleration), the principal disclosed action is the departure of a named executive officer from his role. The filing centers on the departure event and the separation agreement executed in connection with it.","company_name":"ARVINAS, INC.","ticker":"ARVN","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9700,"accession_number":"0001628280-26-044627","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dr. Noah Berkowitz, the Company's chief medical officer, is departing effective July 3, 2026. While the disclosure includes severance terms (base salary continuation, health coverage, and RSU acceleration), the principal disclosed action is the departure of a named executive officer from his role. The filing centers on the departure event and the separation agreement executed in connection with it.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:50:20.441113+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9700,"accession_number":"0001628280-26-044627","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dr. Noah Berkowitz, the Company's chief medical officer, is departing effective July 3, 2026. While the disclosure includes severance terms (base salary continuation, health coverage, and RSU acceleration), the principal disclosed action is the departure of a named executive officer from his role. The filing centers on the departure event and the separation agreement executed in connection with it.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:50:20.441113+00:00","company_name":"ARVINAS, INC.","ticker":"ARVN","filing_date":"2026-06-22"}]}